Skip to main content

Table 6 Strength Outcomes. Studies Comparing Deflazacort and Placebo.

From: Deflazacort for the treatment of Duchenne Dystrophy: A systematic review

Study (Duration of Follow up) B. Angelini, 1994 (12 months) G. Angelini, 1995 (Not stated) N. Brooke, 1996 (3 months)
Strength Measures
Myometer (difference from baseline) DFZ: 1.78 +/- 2.42 kg Placebo: 0.44 +/- 1.37 kg p value: NS - -
MRC score - Improvement in MRC score in both daily and alternate day groups. No numerical values given.  
MRC index * (difference from baseline) DFZ: -2.35 +/- 5.48 Placebo: -9.77 +/- 12.62 p < 0.05 - -
Average muscle score * (difference from baseline) - - DFZ (low): +0.18 (+/- 0.4) DFZ (high): +0.26 (+/- 0.5) Placebo: -0.1 (+/- 0.5) p < 0.0001 Standard errors imputed from p values.
Functional Measures
Timed gait (difference from baseline) DFZ: -0.46 +/- 1.66 Placebo: 2.00 +/- 2.54 p < 0.01 - -
Timed stairs (difference from baseline) DFZ: -1.79 +/- 4.23 Placebo: 3.71 +/- 4.64 p < 0.01 - -
Timed chair (difference from baseline) DFZ: -0.43 +/- 2.65 Placebo: 2.33 +/- 5.20 P value NS - -
Timed Gower (difference from baseline) DFZ: 1.81 +/- 7.18 Placebo: 3.33 +/- 7.18 P value NS - -
Graded gait ** (difference from baseline) DFZ: 0.53 +/- 0.62 Placebo: 1.00 +/- 0.89 P value NS - -
Graded stairs ** (difference from baseline) DFZ: -1.79 +/- 4.23 Placebo: 1.27 +/- 1.01 p < 0.01 - -
Graded chair ** (difference from baseline) DFZ: 0.00 +/- 1.00 Placebo: 1.00 +/- 1.41 p < 0.05 - -
Graded Gower ** (difference from baseline) DFZ: 0.12 +/- 0.78 Placebo: 1.00 +/- 1.18 p < 0.02 - -
Other Measures
Time to loss of ambulation DFZ: 33.2 +/- 9 m Placebo: 20.5 +/- 11 m p < 0.005 - -
  1. A dash represents that this outcome measure was not used. MRC = Medical Research Council * For MRC score, MRC index and muscle score higher scores are more favorable. ** For Graded scores a lower score is more favorable.